Financial Market News

• 13.03.2023

  Insolvency of the financial services provider Silicon Valley Bank

  Last week, the financial services provider Silicon Valley Bank (SVB) was declared insolvent in the USA. »

• 08.07.2022

  A perfect storm in September and October?

  Our investment strategy has followed a cautious approach since the third week of January, and will continue to do so. We recommend equity exposure of no more than 30% to 35% as part of a balanced strategy. »

• 02.08.2019

  Risk increases

  In light of a potential market correction, we are recommending caution and taking profits on the back of this approach. »

• 16.05.2019

  Hedge funds fared well in 2018.

  Our hedge fund portfolios significantly outperformed relevant indices and comparable products in 2018. »

• 14.05.2019

  Difficult 2018

  We were able to largely protect our clients’ assets in what was a difficult 2018. »

• 16.02.2018

  Mandates positive in 2017

  The mandates that we manage ended 2017 positive for the year. »

• 01.06.2017

  Presentable performance

  Since the beginning of this year all our advisory and discretionary mandates and strategies (conservative, balanced, dynamic) have generated returns between 2 % and 10 %. The challenge of the coming months will be to proctect our clients‘ wealth at the right time. »

• 06.10.2016

  Financial crisis

  The financial crisis is not over – but attrative investment alternatives in the financial services sector exist. »

• 04.10.2016

  Rate hike in the US

  An interest rate hike in December in the US is likely and this is anticipated by the markets already »

• 03.10.2016

  Currency pair EUR/CHF

  Will the currency pair EUR/CHF move to parity until spring 2017? »

• 30.09.2016

  Mining stocks

  Mining stocks have left their lowest levels behind – but the selection of single stocks is paying off in this sector. »

• 28.09.2016

  Indian and Brazilian equities

  Will Indian and Brazilian equities again surprise in 2017? »

• 26.09.2016

  Novartis and Roche

  Strategic changes at the Swiss pharma gians Novartis and Roche are conceivable until the end of the year. »